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Introduction 
The objective of this study was to determine the health and performance effects of 
Zuprevo 18% (tildipirosin, 4 mg/kg body weight) during a 42-day backgrounding 
period when administered to high-risk transported cattle within 24 hours after arrival. 
Experimental Procedures
A total of 729 high-risk calves, over 4 phases from 2012–1013, were procured from 
an order buying facility in Dickson, TN. Calves were individually identified, weighed, 
tested for persistent infection with bovine viral diarrhea (BVD-PI), and randomly 
assigned to treatment group pre-shipment. Eight animals that tested positive for 
BVD-PI were removed from the group before shipment. Calves were then transported 
to the Kansas State University Beef Stocker Unit. Upon arrival, calves were housed in 
dirt-surfaced pens overnight with free access to long-stemmed prairie hay and water. 
Within 24 hours of arrival, calves were individually weighed (mean weight 462 lb); 
vaccinated with Cavalry 9 (Schering-Plough Animal Health; Omaha, NE) and either 
Vista 5 (Intervet; Millsboro, DE) or Vista Once (Intervet); dewormed using Safe-guard 
(Intervet) oral drench; and implanted with Ralgro (Schering-Plough Animal Health). 
In addition, calves were mass-medicated with Zuprevo (Merck Animal Health; 
Summit, NJ) or not (Control). Calves were allocated to 56 pens, each containing 12 to 
14 animals. There were 24 pens (309 head) of Control animals and 32 pens (412 head) 
of calves allocated to the Zuprevo treatment during the four study phases. 
All animals were housed and managed the same, with ad libitum access to water and a 
common diet throughout the 42-day study period. Animals were evaluated once daily 
for clinical signs of bovine respiratory disease and observed to ensure appropriate animal 
care management for the duration of the experiment. Personnel responsible for daily 
health monitoring were blinded to treatments. Health status was characterized using a 
clinical scoring system from 0 to 4, with 0 being normal and 4 being moribund, and a 
clinical score for each abnormal animal was recorded daily. Animals with clinical scores 
of 1 (mildly depressed) or 2 (moderately depressed) and a rectal temperature greater 
than 104oF, or animals with clinical scores of 3 (severely depressed) or greater received 
antibiotic therapy. First, second, and third antibiotic treatments for the Zuprevo group 
consisted of Resflor Gold (Intervet, Roseland, NJ), Baytril 100 (Bayer Animal Health, 
Shawnee Mission, KS), and either Bio-mycin 200 (Boehringer Ingelheim, St. Joseph, 
MO) or Excede (Zoetis, Exton, PA), respectively. For the control group, first-round 
treatments consisted of Zuprevo or Resflor Gold, second-round treatments consisted 
of Resflor Gold or Baytril, and third-round antibiotic treatments, when required, 
consisted of Baytril or Excede. Three-day post-treatment moratoriums were observed 
after each antibiotic treatment, with an exception for animals with clinical scores of 3 
or greater that were eligible for retreatment after 48 hours. Animals treated >3 times 
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were deemed chronic. All animals removed from the study for respiratory disease were 
weighed at time of removal, and all mortality cases were necropsied to determine cause 
of death. All animals were individually weighed on day 42 of the studies, and these final 
weights were used to calculate average daily gains and gain efficiencies.
Results and Discussion
Health
Compared with no metaphylaxis at arrival processing (Control), full processing with 
Zuprevo metaphylaxis decreased respiratory disease sickness by 41.8% (P < 0.01), 
increased first-treatment success rates by 17.9% (P = 0.051), decreased chronicity rate 
by 55.9% (P < 0.01), and decreased mortality rate by 25.6% (P = 0.31). Comparisons 
of respiratory disease morbidity rates, case fatality rates, and overall mortality rates all 
revealed significant differences between the control and Zuprevo treatment groups 
(Table 1).
Performance
Compared with no metaphylaxis at arrival, full processing with Zuprevo metaphylaxis 
at arrival increased average daily gain 10.5% (P = 0.03) on a deads-out basis, but not 
when calculated on a deads-in basis (P = 0.36). A non-significant (P = 0.07) trend was 
detected for an interaction between treatment and days on feed for feed intake, which 
is demonstrated in Figure 1. The main effects of days on feed and treatment both were 
significant (P < 0.01). Gain feed efficiency model-adjusted mean pounds of feed per 
head per day for Zuprevo cattle (11.51; SEM = 0.41) were 1.3 pounds higher than 
means for the control, no metaphylaxis treatment (10.21; SEM = 0.41), demonstrat-
ing that Zuprevo metaphylaxis improved feed intakes during the receiving period. No 
significant treatment effects were observed for feed:gain; means and standard errors are 
displayed in Table 2.
Implications
Cattle given Zuprevo had lower bovine respiratory disease morbidity rates than cattle in 
the Control group that were not mass-medicated. The number of calves requiring three 
treatments (chronics) was lower for the Zuprevo group compared with Controls, and 
cattle in the Zupevo group were more efficient when feed efficiency was calculated on a 
deads-out basis. 
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Table 1. Model-adjusted means and corresponding 95% confidence intervals (CI), by treatment group, for 
important health outcomes1
Control  
(24 pens; 309 head)
Zuprevo 
 (32 pens; 412 head)
Item P-value2
Mean 
(SEM)
Lower 
CI
Upper 
CI
Mean 
(SEM)
Lower 
CI
Upper 
CI
Respiratory disease morbidity, % <0.01 65.6 
(5.10)
54.9 74.9 38.2 
(5.01)
28.9 48.5
First-treatment success rate, % 0.051 48.0 
(3.82)
40.5 55.6 58.0 
(4.19)
50.1 66.1
Case fatality rate, % 0.97 9.9 
(2.75)
5.6 16.8 9.3 
(2.92)
5.3 17.3
Chronicity rate (>3 treatments), % <0.01 19.7a 
(3.04)
14.3 26.4 8.7b 
(1.64)
5.8 12.5
Overall mortality rate, % 0.31 7.07 
(1.93)
4.1 12.0 5.25 
(1.45)
3.0 9.0 
1Models included random effects to account for the lack of independence among pens within study phases.
2Where the P-value for an overall treatment effect was <0.10, treatment group means with different superscripts within rows differed 
significantly (P < 0.05).
Table 2. Model-adjusted means and standard errors (SEM) based on results from linear 
mixed models1
Control Zuprevo
Item P-value Mean SEM Mean SEM
Deads-out basis2
Average daily gain, lb 0.03 2.46 0.15 2.75 0.13
Feed:gain 0.40 4.41 0.28 4.59 0.25
Deads-in basis
Average daily gain, lb 0.36 2.33 0.38 2.49 0.37
Feed:gain 0.52 4.81 1.79 6.01 1.60
1Models included random effects to account for the lack of independence among pens within study phases.
2 Deads-out data were not included for Phase 1 [analyses will be re-run on receipt of these data].
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Figure 1. Daily dry matter intake (DMI) by treatment group over the feeding period.
